Morocco’s Laprophan pharmaceutical group has finalized the acquisition of a majority stake in Rivopharm, a Swiss company specializing in specialty medicines, complex pharmaceutical formulations and high-value regulatory expertise, reported medias24. The deal, completed on June 17, marks Laprophan’s first European acquisition and what its president describes as a historic milestone for Moroccan pharmaceutical industry on the international stage.
Financial terms were not disclosed. Rivopharm generates annual revenues of approximately $100 million. The transaction was executed through Europhan, Laprophan’s European holding vehicle based in Luxembourg, and brings with it a portfolio of strategic assets: Rivopharm’s industrial site in Lugano — approved by the US FDA, Swissmedic, Australia’s Therapeutic Goods Administration and European authorities — along with three subsidiaries: Rivopharm UK, Holsten Pharma in Germany and Sanoswiss in Lithuania.
According to the media, the company’s product portfolio encompasses approximately 125 molecules and nearly 1,500 commercial references sold across more than 30 countries, backed by licensing agreements with major international generic manufacturers.
For Laprophan, already present internationally through offices in India, the UAE and Côte d’Ivoire, the acquisition constitutes a step-change in scale and geographic reach. It opens direct access to multiple strategic European markets and substantially broadens the group’s industrial and commercial footprint.
Dr Farid Bennis, Laprophan’s president, called the deal “a decisive moment” in the company’s history, describing it as “a historical first: Moroccan medicine is recognized internationally and in Switzerland, the country of the world pharmaceutical industry.” Integration work has already begun, with synergies expected across pharmaceutical development, manufacturing, regulatory management and commercial operations.
The acquisition advances Laprophan’s stated ambition of building a pharmaceutical platform spanning Europe, Africa and the Middle East, and opens new growth avenues in B2B pharmaceutical activities — including licensing and regulatory dossier development — that the group sees as an important driver of future revenues.
